The goal of the University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Career Development Program (CDP) is to develop knowledgeable, well-trained scientists experienced in multidisciplinary research for future studies in translational lymphoma research. The provision of ample opportunities for training and career enhancement is a top priority of the University of lowa and Mayo Clinic scientific communities. The CDP represents a key growth'' area within the UI/MC SPORE and allows us to recruit two bright, energetic new investigators into SPORE research. The extensive research and training base available at these two institutions provides strong support for the SPORE CDP. The primary objective of the CDP is to train young investigators (senior postdoctoral fellows and young faculty) in translational, multidisciplinary basic, clinical or population-based lymphoma research. During this most recent funding period (years 5-9), 5 young investigators received CDP awards and were each supported for 1-2 years. They all remain active translational lymphoma investigators within the SPORE. The SPORE CDP will provide up to $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from the University of lowa and Mayo Clinic resources) for each of two awards. An additional year of support is possible based on progress and successful re-competition. During the next funding period, the UI/MC Lymphoma SPORE will maintain: (1) a stringent candidate selection system; (2) comprehensive trainee guidance by a menter; (3) support through a scientific mentor group (the Individual Trainee Mentorship Committee) comprised of investigators with expertise in each trainee's area of interest; (4) multi-disciplinary research courses and on-going training activities such as the Multidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites; (5) encouragement of collaboration with Investigator Group meetings at both sites; (6) encouragement of collaboration with investigators at both lowa and Mayo and (7) opportunities for research enhancement through the Developmental Research Program.

Public Health Relevance

The UI/MC SPORE CDP will provide support for integrated training and education to new investigators committed to careers in lymphoma translational research. The CDP is designed to provide breadth and flexibility to awardees who require additional research knowledge and skills in order to compete for independent extramural grant support and contribute to the UI/MC SPORE. The CDP has been very successful over the last 9 years at accomplishing these goals. The CDP will continue as a research experience under the mentorship of established SPORE investigators and supported by SPORE-funded Core resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
4P50CA097274-15
Application #
9115095
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
15
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52246
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598
Pophali, Priyanka A; Ip, Andrew; Larson, Melissa C et al. (2018) The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93:1543-1550

Showing the most recent 10 out of 387 publications